Project Grant R43HL149145

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $323,230 Project Grant to Sirona Medical Technologies, Inc. to develop a multi-channel radiofrequency and pulsed field energy source generator for cardiac ablation. The goal of this R61 phase award is to develop and validate hardware to interface Sirona's proprietary catheter technology with RF and PF generator platforms, establish safe and effective signal...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $395,306 to Cutcath LLC to develop and evaluate a novel electrosurgical catheter device for treating acute aortic dissection. The device, called the Cutcath Dissection Septum Cutting Catheter (DSCC), aims to facilitate more effective endovascular aortic repair (TEVAR/EVAR) by allowing complete fenestration of the aortic dissection septum....

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) awarded Sigt LLC a $293,880 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program. The purpose of this Phase 1 SBIR grant is to develop a novel "Intraoperative Cardiac Pulsed Field Ablation Lesion Assessment System" (PFA-LAS) that can monitor procedure parameters and confirm durable lesion formation during cardiac pulsed electric field ablation procedures for atrial...

Corveus Medical, Inc. was awarded a $255,841 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop an extravascular bipolar catheter for targeted nerve ablation with minimal collateral damage to surrounding tissues. The grant aims to support the design and prototyping of a minimally invasive, catheter-delivered venous procedure for performing extravascular greater splanchnic nerve ablation. The proposed catheter...

The National Heart, Lung, and Blood Institute (NHLBI) has awarded a Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of Columbia University in the City of New York. The $688,291 grant will fund the development and clinical validation of a novel 3D ultrasound technique called Electromechanical Wave Imaging (EWI) for non-invasive, personalized cardiac arrhythmia mapping. Over a 5-year period ending in June 2029, the project aims to demonstrate that...

This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...

This $977,998.39 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund a clinical trial to evaluate the use of venous ethanol ablation (VE) in combination with radiofrequency (RF) catheter ablation for treating ischemic ventricular tachycardia (VT). The trial, titled "Venous Ethanol for Left Ventricular Ischemic Ventricular Tachycardia (VELVET)", will compare the efficacy and safety of...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $413,595 Project Grant to Unandup, LLC, a medical technology firm based in St. Louis, Missouri. The grant will fund the development of a magnetic rotational atherectomy platform to debulk severely calcified coronary lesions and improve percutaneous coronary intervention procedures. Key innovations include the use of magnetic fields to control the atherectomy...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...

Rochester Institute of Technology (RIT) received a $248,480 Project Grant award from the National Science Foundation Division of Chemical, Bioengineering, Environmental, and Transport Systems under the Engineering federal grant program (CFDA 47.041) to develop an interactive, data-enabled scientific computing platform for characterizing and monitoring cardiac tissue ablation. Through leveraging expertise in heat transfer theory, image computing, biomedical modeling and simulation, and...